caffeine has been researched along with ALS - Amyotrophic Lateral Sclerosis in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Caffeine is associated with a lower risk of some neurological diseases, but few prospective studies have investigated caffeine intake and risk of amyotrophic lateral sclerosis (ALS) mortality." | 7.91 | Coffee, tea, and caffeine intake and amyotrophic lateral sclerosis mortality in a pooled analysis of eight prospective cohort studies. ( Adami, HO; Buring, J; English, DR; Freedman, DM; Giles, GG; Håkansson, N; Kurth, T; Larsson, SC; O'Reilly, É; Petimar, J; Robien, K; Schouten, LJ; Smith-Warner, SA; van den Brandt, PA; Weiderpass, E; Wolk, A, 2019) |
| "Caffeine intake was not associated with ALS risk; the pooled multivariable-adjusted RR comparing the highest to the lowest quintile of intake was 0." | 5.42 | Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: Results from five cohort studies. ( Ascherio, A; Falcone, GJ; Fitzgerald, KC; Fondell, E; Gapstur, SM; Kolonel, LN; O'Reilly, ÉI; Park, Y, 2015) |
| "Caffeine is a nonselective adenosine receptor antagonist; chronic consumption has proved protective toward neurodegenerative diseases such as Parkinson's and Alzheimer's diseases." | 5.39 | Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. ( Armida, M; Ferrante, A; Matteucci, A; Pèzzola, A; Popoli, P; Potenza, RL; Puopolo, M, 2013) |
| "Riluzole clearance was estimated from serum drug concentration measurements followed by Bayesian fitting." | 5.33 | Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. ( Groeneveld, GJ; Guchelaar, HJ; Kalmijn, S; Spieksma, M; van den Berg, LH; van Kan, HJ, 2005) |
| "Caffeine is associated with a lower risk of some neurological diseases, but few prospective studies have investigated caffeine intake and risk of amyotrophic lateral sclerosis (ALS) mortality." | 3.91 | Coffee, tea, and caffeine intake and amyotrophic lateral sclerosis mortality in a pooled analysis of eight prospective cohort studies. ( Adami, HO; Buring, J; English, DR; Freedman, DM; Giles, GG; Håkansson, N; Kurth, T; Larsson, SC; O'Reilly, É; Petimar, J; Robien, K; Schouten, LJ; Smith-Warner, SA; van den Brandt, PA; Weiderpass, E; Wolk, A, 2019) |
| "Caffeine intake was not associated with ALS risk; the pooled multivariable-adjusted RR comparing the highest to the lowest quintile of intake was 0." | 1.42 | Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: Results from five cohort studies. ( Ascherio, A; Falcone, GJ; Fitzgerald, KC; Fondell, E; Gapstur, SM; Kolonel, LN; O'Reilly, ÉI; Park, Y, 2015) |
| "Caffeine is a nonselective adenosine receptor antagonist; chronic consumption has proved protective toward neurodegenerative diseases such as Parkinson's and Alzheimer's diseases." | 1.39 | Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. ( Armida, M; Ferrante, A; Matteucci, A; Pèzzola, A; Popoli, P; Potenza, RL; Puopolo, M, 2013) |
| "Riluzole clearance was estimated from serum drug concentration measurements followed by Bayesian fitting." | 1.33 | Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. ( Groeneveld, GJ; Guchelaar, HJ; Kalmijn, S; Spieksma, M; van den Berg, LH; van Kan, HJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salado, IG | 1 |
| Redondo, M | 1 |
| Bello, ML | 1 |
| Perez, C | 1 |
| Liachko, NF | 1 |
| Kraemer, BC | 1 |
| Miguel, L | 1 |
| Lecourtois, M | 1 |
| Gil, C | 2 |
| Martinez, A | 2 |
| Perez, DI | 1 |
| Nozal, V | 1 |
| Martínez-González, L | 1 |
| Gomez-Almeria, M | 1 |
| Gonzalo-Consuegra, C | 1 |
| Santana, P | 1 |
| Chaikuad, A | 1 |
| Pérez-Cuevas, E | 1 |
| Knapp, S | 1 |
| Lietha, D | 1 |
| Ramírez, D | 1 |
| Petralla, S | 1 |
| Monti, B | 1 |
| Martín-Requero, A | 1 |
| Palomo, V | 1 |
| de Lago, E | 1 |
| Rei, N | 2 |
| Valente, CA | 2 |
| Vaz, SH | 2 |
| Farinha-Ferreira, M | 2 |
| Ribeiro, JA | 2 |
| Sebastião, AM | 2 |
| Petimar, J | 1 |
| O'Reilly, É | 1 |
| Adami, HO | 1 |
| van den Brandt, PA | 1 |
| Buring, J | 1 |
| English, DR | 1 |
| Freedman, DM | 1 |
| Giles, GG | 1 |
| Håkansson, N | 1 |
| Kurth, T | 1 |
| Larsson, SC | 1 |
| Robien, K | 1 |
| Schouten, LJ | 1 |
| Weiderpass, E | 1 |
| Wolk, A | 1 |
| Smith-Warner, SA | 1 |
| Fondell, E | 1 |
| O'Reilly, ÉI | 1 |
| Fitzgerald, KC | 1 |
| Falcone, GJ | 1 |
| Kolonel, LN | 1 |
| Park, Y | 1 |
| Gapstur, SM | 1 |
| Ascherio, A | 1 |
| Potenza, RL | 1 |
| Armida, M | 1 |
| Ferrante, A | 1 |
| Pèzzola, A | 1 |
| Matteucci, A | 1 |
| Puopolo, M | 1 |
| Popoli, P | 1 |
| van Kan, HJ | 1 |
| Groeneveld, GJ | 1 |
| Kalmijn, S | 1 |
| Spieksma, M | 1 |
| van den Berg, LH | 1 |
| Guchelaar, HJ | 1 |
| Il'ina, NA | 1 |
| Poliakova, NF | 1 |
| Khokhlov, AP | 1 |
8 other studies available for caffeine and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Benzothiazoles; Blood-Brain B | 2014 |
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain; Case-Control Studies; DNA-Binding Proteins; Humans; I | 2022 |
Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Modulation by chronic caffeine.
Topics: Adenosine; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrophic Factor; Caffeine; Dise | 2022 |
Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Modulation by chronic caffeine.
Topics: Adenosine; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrophic Factor; Caffeine; Dise | 2022 |
Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Modulation by chronic caffeine.
Topics: Adenosine; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrophic Factor; Caffeine; Dise | 2022 |
Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Modulation by chronic caffeine.
Topics: Adenosine; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrophic Factor; Caffeine; Dise | 2022 |
Coffee, tea, and caffeine intake and amyotrophic lateral sclerosis mortality in a pooled analysis of eight prospective cohort studies.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Caffeine; Coffee; Female; Humans; Mal | 2019 |
Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: Results from five cohort studies.
Topics: Aged; Amyotrophic Lateral Sclerosis; Caffeine; Coffee; Cohort Studies; Female; Humans; Male; Middle | 2015 |
Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Animals; Body Weight; Caffeine; Disease Models, | 2013 |
Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amyotrophic Lateral Sclerosis; Anticonvulsants; Caffe | 2005 |
[Pathogenesis of creatinuria and aminoaciduria in neuromuscular diseases].
Topics: Adolescent; Adult; Amino Acids; Amyotrophic Lateral Sclerosis; Caffeine; Child; Child, Preschool; Cr | 1977 |